Immunoproliferative Disorders  >>  Gazyva (obinutuzumab)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

8 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Gazyva (obinutuzumab) / Roche, Biogen
NCT00576758 / 2008-003460-19: GAUSS: A Study of Obinutuzumab (RO5072759) in Patients With Indolent Non-Hodgkin's Lymphoma

Checkmark BSH 2015
Apr 2015 - Apr 2015: BSH 2015
Checkmark P2 data - ASCO
Jun 2012 - Jun 2012: P2 data - ASCO
Checkmark P2 data
More
Completed
2
175
US, Canada, Europe, RoW
obinutuzumab (RO5072759), RO5072759, GA101, GAZYVA®, rituximab
Hoffmann-La Roche
Non-Hodgkin's Lymphoma
09/11
03/13
NCT01414205: A Study Comparing Obinutuzumab (RO5072759; GA101) 1000 Milligram (mg) Versus 2000 mg in Participants With Previously Untreated Chronic Lymphocytic Leukemia (CLL) (GAGE)

Checkmark ASCO 2014
May 2014 - May 2014: ASCO 2014
Checkmark For CLL
Jun 2013 - Jun 2013: For CLL
Completed
2
80
US
Obinutuzumab, RO5072759; GA101, Corticosteroids
Genentech, Inc.
Lymphocytic Leukemia, Chronic
03/13
03/16
GATHER, NCT01414855: A Study of Obinutuzumab [RO5072759 (GA101)] in Combination With CHOP Chemotherapy in Patients With Previously Untreated Advanced Diffuse Large B-Cell Lymphoma

Checkmark ASH 2013
Nov 2013 - Nov 2013: ASH 2013
Checkmark ASH 2013
Nov 2013 - Nov 2013: ASH 2013
Completed
2
100
US
obinutuzumab, cyclophosphamide, doxorubicin, prednisone, vincristine
Genentech, Inc.
Lymphoma, B-Cell
12/13
12/16
NCT01868893: An Expanded Access, Open-Label Study of Obinutuzumab (GA101) Plus Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia

Checkmark Presentation of data for stage II CLL11 trial at ASH 2013
Dec 2013 - Dec 2013: Presentation of data for stage II CLL11 trial at ASH 2013
Completed
2
20
US
Obinutuzumab, RO 5072759, GA101, Chlorambucil
Genentech, Inc.
Chronic Lymphocytic Leukemia
01/14
01/14
NCT01889797: Phase II Randomized Trial Comparing GA101 and Rituximab in Untreated Low Tumor Burden Indolent Non-Hodgkin's Lymphoma

Terminated
2
32
US
Arm A: Rituximab, IDEC-C2B8, Chimeric anti-CD20 monoclonal antibody, Rituxan, NSC# 687451, Arm B: GA101, Obinutuzumab, RO5072759, huMAB
PrECOG, LLC., Genentech, Inc.
Indolent Non-Hodgkin's Lymphoma
04/16
08/16
NCT02420210: Bendamustine, Obinutuzumab, and Dexamethasone in Older Patients With Diffuse Large B-cell Lymphoma

Terminated
2
2
US
Bendamustine Hydrochloride, Ribomustin, SyB L-0501, Treanda, Obinutuzumab, Anti-CD20 Monoclonal Antibody R7159, GA101, Gazyva, R7159, RO 5072759, Dexamethasone, DM, Quality-of-Life Assessment, Quality of Life Assessment, Laboratory Biomarker Analysis
University of Chicago, National Cancer Institute (NCI)
Diffuse Large B-Cell Lymphoma
08/16
08/16
ICLL-07, NCT02666898: Phase II Trial GA101 Inbrutinib B CLL

Completed
2
135
Europe
GA101, Obinutuzumab, Ibrutinib, Imbruvica, Cyclophosphamide, Endoxan, Fludarabine, Fludara
French Innovative Leukemia Organisation, Roche Pharma AG, Janssen-Cilag Ltd.
Leukemia, Lymphocytic, Chronic, B-Cell
05/17
03/18
NCT02371590: Lenalidomide and Obinutuzumab for Previously Untreated CLL

Withdrawn
2
0
US
Lenalidomide, Revlimid, Obinutuzumab, Gazyva
University of California, San Diego, Celgene Corporation, Genentech, Inc.
Chronic Lymphocytic Leukemia
12/19
12/22

Download Options